CITIUS PHARMACEUTICALS INC's ticker is CTXR and the CUSIP is 17322U207. A total of 74 filers reported holding CITIUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,266 | -18.4% | 28,151 | +43.0% | 0.00% | – |
| Q2 2023 | $23,624 | -84.7% | 19,687 | -85.1% | 0.00% | – |
| Q1 2023 | $154,336 | -68.9% | 131,911 | -79.0% | 0.00% | – |
| Q4 2022 | $496,652 | +19.4% | 628,673 | +82.8% | 0.00% | – |
| Q3 2022 | $416,000 | +5.1% | 343,878 | -20.1% | 0.00% | – |
| Q2 2022 | $396,000 | -16.6% | 430,570 | +62.2% | 0.00% | – |
| Q1 2022 | $475,000 | +27.0% | 265,421 | +9.2% | 0.00% | – |
| Q4 2021 | $374,000 | -28.8% | 243,014 | -6.1% | 0.00% | – |
| Q3 2021 | $525,000 | -27.9% | 258,773 | +23.7% | 0.00% | – |
| Q2 2021 | $728,000 | +1356.0% | 209,208 | +646.9% | 0.00% | – |
| Q1 2021 | $50,000 | +163.2% | 28,009 | +48.3% | 0.00% | – |
| Q4 2020 | $19,000 | -5.0% | 18,891 | +8.3% | 0.00% | – |
| Q2 2020 | $20,000 | +233.3% | 17,437 | +63.7% | 0.00% | – |
| Q1 2020 | $6,000 | -84.2% | 10,652 | -59.9% | 0.00% | – |
| Q1 2019 | $38,000 | – | 26,568 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Inspire Advisors, LLC | 196,867 | $181,000 | 0.05% |
| Wealth Advisory Solutions, LLC | 156,850 | $144,000 | 0.04% |
| Horst & Graben Wealth Management LLC | 75,722 | $70,000 | 0.02% |
| Ergoteles LLC | 451,890 | $416,000 | 0.01% |
| Miller Investment Management, LP | 50,000 | $46,000 | 0.01% |
| Virtu Financial LLC | 81,410 | $75,000 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 17,342 | $16,000 | 0.00% |
| Kestra Advisory Services, LLC | 71,102 | $65,000 | 0.00% |
| Csenge Advisory Group | 15,000 | $14,000 | 0.00% |
| Qube Research & Technologies Ltd | 121,281 | $112,000 | 0.00% |